Aldosterone Blockade: An Emerging Strategy for Abrogating Progressive Renal Disease

American Journal of Medicine

Volumn 119, Issue 11, 2006, Pages 912-919

  Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Albuminuria; Aldosterone; Mineralocorticoid receptor; Progressive renal disease; Selective aldosterone blockade

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; IRBESARTAN; LOSARTAN; PLASMINOGEN ACTIVATOR INHIBITOR 1; POTASSIUM; PROTEIN; RAMIPRIL; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1;

ALGORITHM; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GYNECOMASTIA; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY DISTAL TUBULE; KIDNEY FIBROSIS; KIDNEY INJURY; MASTALGIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; PROTEINURIA; RAT STRAIN; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ALGORITHMS; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; DRUG LABELING; FIBROSIS; HEART FAILURE, CONGESTIVE; HUMANS; HYPERKALEMIA; KIDNEY; KIDNEY FAILURE; RENAL AGENTS; SPIRONOLACTONE;

EID: 33750350450     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2006.03.038     Document Type: Review

References (56)

1. Edelman I.S., and Fimognari G.M. On the biochemical mechanism of action of aldosterone. Recent Prog Horm Res 24 (1968) 1-44
2. Rossier B.C. Mechanisms of action of mineralocorticoid hormones. Endocr Res 15 (1989) 206-226
3. Tan L.B., Schlosshan D., and Barker D. Fiftieth anniversary of aldosterone: from discovery to cardiovascular therapy. Int J Cardiol 96 (2004) 321-333
4. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 19 (2001) 829-842
5. Hostetter T.H., and Ibrahim H.N. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol 24 (2003) 2395-2401
6. Stier C.T., Koenig S., Lee D.Y., et al. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra). Heart Dis 5 (2003) 102-118
7. Duprez D., De Buyzere M., Rietzchel E.R., and Clement D.L. Aldosterone and vascular damage. Curr Hypertens Rep 2 (2000) 327-334
8. Bonvalet J.P., Alfaidy N., Farman N., and Lombes M. Aldosterone: intracellular receptors in human heart. Eur Heart J 16 suppl N (1995) 92-97
9. Kornel L. Colocalization of 11β-hydroxysteroid dehydrogenase and mineralocorticoid receptors in cultured vascular smooth muscle cells. Am J Hypertens 7 (1994) 100-103
10. Lombes M., Oblin M.E., Gasc J.M., et al. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71 (1992) 503-510
11. Young M., Fullerton M., Dilley R., and Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 93 (1994) 2578-2583
12. Wakisaka M., Spiro M.J., and Spiro R.G. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 43 (1994) 95-103
13. Epstein M. Aldosterone as a determinant of progressive renal dysfunction: a paradigm shift. NephSAP 3 (2004) 285-295
14. Brown N.J., Kim K.S., Chen Y.Q., et al. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. J Clin Endocrinol Metab 85 (2000) 336-344
15. Brown N.J., Nakamura S., Ma L., et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58 (2000) 1219-1227
16. Sun Y., Zhang J., Zhang J.Q., and Ramires F.J. Local angiotensin II and transforming growth factor-beta1 in renal fibrosis of rats. Hypertension 35 (2000) 1078-1084
17. Stier Jr. C., Zuckerman A., Harashima H., and Chander P. Antioxidants reduce aldosterone-induced renal vascular injury in stroke-prone SHR. [abstract]. J Am Soc Nephrol 110 (1999) 400A
18. Schiffrin E.L., Franks D.J., and Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 63 (1985) 1522-1527
19. Brown N.J., Vaughan D.E., and Fogo A.B. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Semin Nephrol 22 (2002) 399-406
20. Brown N.J., Agirbasli M.A., Williams G.H., et al. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-I. Hypertension 32 (1998) 965-971
21. Quan Z.Y., Walser M., and Hill G.S. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 41 (1992) 326-333
22. Gavras H., Brunner H.R., Laragh J.H., et al. Malignant hypertension resulting from deoxycortisone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res 36 (1975) 300-309
23. Rocha R., Chander P.N., Khanna K., et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31 (1998) 451-458
24. Rocha R., Chander P.N., Zuckerman A., and Stier Jr. C.T. Role of mineralocorticoids in renal injury in stroke-prone hypertensive rats. [abstract]. Hypertension 32 (1998) 598
25. Greene E., Kren S., and Hostetter T.H. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98 (1996) 1063-1068
26. Rocha R., Chander P.N., Zuckerman A., and Stier C.T. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33 (1999) 232-237
27. Rocha R., Stier Jr. C.T., Kifor I., et al. Aldosterone: a mediator of myocardial necrosis and renal arteriolopathy. Endocrinology 141 (2000) 3871-3878
28. Blasi E.R., Rocha R., Rudolph A.E., et al. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003) 1791-1800
29. Feria I., Pichardo I., Juarez P., et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63 (2003) 43-52
30. Zhou X., Ono H., Ono Y., and Frohlich E.D. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics in L-NAME/SHR model. Am J Nephrol 24 (2004) 242-249
31. Epstein M., Buckalew V., Martinez F., et al. Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination in diabetic hypertensives with microalbuminuria. [abstract]. Am J Hypertens 15 (2002) 24A
32. Epstein M., Williams G.H., Weinberger M., et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1 (2006) 940-951
33. Rachmani R., Slavachevsky I., Amit M., et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21 (2004) 471-475
34. Rossing K., Schjoedt K.J., Smidt U.M., et al. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28 (2005) 2106-2112
35. Schjoedt K.J., Rossing K., Juhl T.R., et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68 (2005) 2829-2836
36. Sato A., Hayashi K., and Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18 (2005) 44-49
37. Bianchi S., Bigazzi R., and Campese V.M. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 46 (2005) 45-51
38. Chrysostomou A., Pedagogos E., MacGregor L., and Becker G.J. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1 (2006) 256-262
39. Meyer T.W., Anderson S., Rennke H.G., and Brenner B.M. Reversing glomerular hypertension stabilizes established glomerular injury. Kidney Int 31 (1987) 752-759
40. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., and The Collaborative Study Group. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
41. Ruggenenti P., Perna A., Gherardi G., et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352 (1998) 1252-1256
42. Staessen J., Lijnen P., Fagard R., et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91 (1981) 457-465
43. Biollaz J., Brunner H.R., Gavras I., et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 4 (1982) 966-972
44. McKelvie R.S., Yusuf S., Pericak D., et al., The RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: a randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100 (1999) 1056-1064
45. Sato A., and Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens 16 (2003) 781-788
46. Schjoedt K.J., Andersen S., Rossing P., et al. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47 (2004) 1936-1939
47. Pitt B., Zannad F., and Remme W.J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
48. Delyani J.A. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 57 (2000) 1409-1411
49. Pitt B., Remme W., Zannad F., et al. for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
50. Epstein M., Alexander J.C., and Roniker B. Efficacy and safety of eplerenone, a novel and selective aldosterone receptor antagonist (SARA), in patients with mild to moderate hypertension. [abstract]. Hypertension 33 (1999) 1075
51. Weinberger M.H., Roniker B., Krause S.L., and Weiss R.J. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens 15 (2002) 709-716
52. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension 40 (2002) 117-123
53. Allon M. Hyperkalemia in end-stage renal disease: mechanisms and management. J Am Soc Nephrol 6 (1995) 1134-1142
54. Juurlink D.N., Mamdani M.M., and Lee D.S. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
55. Svensson M., Gustafsson F., Galatius S., et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. J Card Fail 10 (2004) 297-303
56. Sica D.A. Eplerenone: a new aldosterone receptor antagonist-are the FDA's restrictions appropriate?. J Clin Hypertens 5 (2002) 441-445